Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation

Abstract

Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality with limited treatment options. Lung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipients with this problem. In the present study, we reported six patients who underwent LTX due to BOS after HSCT (two females, four males) from January 2012 to December 2014 in our center. The median time from HSCT to diagnosis of BOS was 2.5 years (ranging from 1 to 5 years). At a median time of 4 years (ranging from 2 to 5 years) after diagnosis of BOS, four patients received bilateral sequential LTX, and two patients received single LTX. One of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung graft dysfunction on post-operation day 2, and three experienced fungal infections. The median time for follow-up after LTX was 19.5 months (ranging from 12 to 39 months). At present, all patients are alive with good functional capacity and no relapse of BOS and hematologic malignancy conditions. Patients who received bilateral LTX have better pulmonary functions than patients who received single LTX.

Keywords

bronchiolitis obliterans syndrome (BOS) / hematopoietic stem cell transplantation (HSCT) / lung transplantation (LTX)

References

[1] Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Litzow MR. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100(4): 680–687

[2] Afessa B, Peters SG. Chronic lung disease after hematopoietic stem cell transplantation. Clin Chest Med 2005; 26(4): 571–586

[3] Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17(7): 1072–1078

[4] Soubani AO, Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 2007; 29(5): 1007–1019

[5] Redel-Montero J, Bujalance-Cabrera C, Vaquero-Barrios JM, Santos-Luna F, Arenas-De Larriva M, Moreno-Casado P, Espinosa-Jiménez D. Lung transplantation for bronchiolitis obliterans after allogenic bone marrow transplantation. Transplant Proc 2010; 42(8): 3023–3025

[6] Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, Nishimura M. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003; 102(12): 4236–4242

[7] Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9(10): 657–666

[8] Holm AM, Riise GC, Hansson L, Brinch L, Bjørtuft O, Iversen M, Simonsen S, Fløisand Y. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant 2013; 48(5): 703–707

[9] Vogl UM, Nagayama K, Bojic M, Hoda MA, Klepetko W, Jaksch P, Dekan S, Siersch V, Mitterbauer M, Schellongowski P, Greinix HT, Petkov V, Schulenburg A, Kalhs P, Rabitsch W. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation 2013; 95(4): 623–628

[10] Rampolla R. Lung transplantation: an overview of candidacy and outcomes. Ochsner J 2014; 14(4): 641–648

[11] Soubani AO, Kingah P, Alshabani K, Muma G, Haq A. Lung transplantation following hematopoietic stem cell transplantation: report of two cases and systematic review of literature. Clin Transplant 2014; 28(7): 776–782

[12] van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, Bishop MR. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010; 16(1 Suppl): S138–S145

[13] Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999; 116(1): 127–133

[14] Garrity ER Jr, Villanueva J, Bhorade SM, Husain AN, Vigneswaran WT. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71(6): 773–777

[15] Hartwig MG, Snyder LD, Appel JZ 3rd, Cantu E 3rd, Lin SS, Palmer SM, Davis RD. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008; 27(5): 547–553

[16] Hartert M, Senbaklavacin O, Gohrbandt B, Fischer BM, Buhl R, Vahld CF. Lung transplantation: a treatment option in end-stage lung disease. Dtsch Arztebl Int 2014; 111(7): 107–116

[17] Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int 2007; 20(12): 993–1015

[18] Solé A, Morant P, Salavert M, Pemán J, Morales P; Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11(5): 359–365

[19] Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008; 22(2): 89–104

Compliance with ethics guidelines

Fei Gao, Jingyu Chen, Dong Wei, Bo Wu, and Min Zhou declare that they have no conflicts of interest. Ethical approval was given by the Medical Ethics Committee of Transplantation.

RIGHTS & PERMISSIONS

2017 Higher Education Press and Springer-Verlag Berlin Heidelberg